MedTrace Logo

Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis

NCT07340892 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-02-04

No results posted yet for this study

Summary

Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of precise and effective diagnostic techniques often leads to underdiagnosis and misdiagnosis. The investigators conducted a prospective clinical study to evaluate the effectiveness of ¹H-nuclear magnetic resonance (NMR)-based lipoprotein and metabolite analysis in diagnosing checkpoint inhibitor-related pneumonitis (CIP), aiming to improve its early diagnosis rate.

Conditions

  • Checkpoint Inhibitor-related Pneumonitis

Sponsors & Collaborators

  • Zhou Chengzhi

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-10
Primary Completion
2027-01-10
Completion
2028-01-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07340892 on ClinicalTrials.gov